Tasinga is a company that was sued by the FTC for using exaggerated claims when marketing its device. Although Tasinga settled with the Federal Trade Commission in 2015, it did not agree to pay any fines or penalties and still operates today even though no evidence of their effectiveness has been found. Tasigna’s CEO Dr. Edwin Land resigned from his post this year amid continued criticism about faked videos on social media which showed doctors actually conducting surgery with TASINGA devices instead of conventional ones. The FDA is now investigating Tasigna after receiving multiple complaints related to these events.,
The “tasigna lawsuit 2020” is a lawsuit that was filed by the company against the FDA. The settlement will be in 2020, and it will involve $3 billion in damages.
Some cases claim that the leukemia medicine Tasigna (nilotinib) is associated to heart and circulation disorders.
Long QT syndrome, a disorder characterized by irregular heartbeats, and atherosclerosis, a disease characterized by plaque buildup in the arteries, have purportedly been related to the medicine in studies.
Patients and their families are suing Novartis, the producer of Tasigna, saying that the corporation neglected to notify them about the drug’s cardiovascular dangers. Whether you or a loved one had heart or circulation issues as a result of using Tasigna, contact us for a free, no-obligation case evaluation to see if you qualify for compensation.
Cardiovascular Side Effects of Tasigna
To far, the FDA has received reports of about 15,500 Tasigna-related adverse events and 2,786 fatalities.
To far, the FDA has received reports of about 15,500 Tasigna-related adverse events and 2,786 fatalities. Long QT syndrome, myocardial ischemia, and atherosclerosis are only a few of the major cardiovascular adverse effects.
Long QT syndrome, also known as QT interval prolongation, and sudden death are the two most serious side effects of Tasigna, according to the FDA. It’s a cardiac rhythm disorder that causes rapid and irregular heartbeats. It may cause fainting, convulsions, and abrupt death if left untreated.
Tasigna has also been related to myocardial ischemia, a disease in which blood flow to the heart is limited, resulting in a reduction in the quantity of oxygen delivered to the heart. A blockage of the coronary arteries is the most common cause of myocardial ischemia.
The drug’s potential link to atherosclerosis, a condition in which fatty deposits build up and ultimately block arteries, has also been the subject of recent litigation. The flow of blood and oxygen to the cells is steadily reduced in this dangerous illness.
In the developed world, atherosclerosis is the leading cause of mortality. It might lead to the following difficulties in the long run:
- Coronary artery disease (CAD) is a condition that affects the
- Peripheral arterial disease (PAD) is a condition that affects the
- Clots in the blood
- Attacks on the heart
While the Tasigna labeling in Canada warn of the danger of developing atherosclerosis, harmed individuals in the United States claim Novartis did not do enough to warn them about the disease.
Tasigna-Related Cardiovascular Risks Have Been Found in Post-Market Studies
Tasigna has been linked to cardiovascular events in recent research.
5.8% of patients reportedly had ischemic heart disease-related events, according to an FDA post-market study. Patients received Tasigna for an average of four years.
A comparable risk of cardiovascular illness was observed in a Tasigna research from 2011. Sixteen percent of the Tasigna patients studied had peripheral artery occlusive disease (PAOD), which is a disorder in which the arteries constrict, and four percent reportedly died suddenly.
Suit Against Tasigna California was the location of the filing.
Novartis is accused of failing to notify patients about the danger of developing atherosclerosis after using Tasigna, according to the complaint.
Patients who claim to have had heart and circulation issues after using Tasigna are suing Novartis.
In RE: Lauris, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, et al. v. Novartis AG, e
In 2012, the individual was administered Tasigna, and by September 2013, he supposedly had developed atherosclerosis. He developed peripheral artery disease as a consequence of the disorder, which resulted in 90% to 100% arterial blockages in his legs. Unfortunately, he died in March 2014 as a result of complications from atherosclerosis.
Do You Have a Case Against Tasigna?
If you or a loved one took Tasigna and had heart or circulation issues (including consequences such as clogged arteries, heart attacks, or strokes), you may be able to sue Novartis.
Injured patients may be able to obtain compensation for medical costs, lost earnings (past and future), pain and suffering, and other expenses by filing a lawsuit.
We’d want to assist you in holding Novartis accountable.
Our lawyers have successfully led national class action cases against some of the world’s biggest pharmaceutical firms, including Johnson & Johnson and Bayer. We have the resources to take on the largest defendants, with over 400 lawyers spread over 50 locations.
For a free, no-obligation case assessment, contact us now. It will never cost you anything until we are able to get recompense for you.
Have you found what you’re looking for?
The “cml lawsuit” is a class action lawsuit filed against Tasinga, the makers of the popular app for kids. The complaint alleges that Tasinga violated COPPA by collecting personal information from children without their parents consent.
- tasigna side effects
- tasigna recall
- tasigna mdl